OrbiMed’s Sudden Sell‑off Sparks New Liquidity Wave at Adicet Bio, Raising Questions About Institutional Confidence

Insider Selling Spurs a Fresh Wave of Activity at Adicet Bio

A cluster of sell‑orders from the OrbiMed family of funds on April 7–8, 2026 has injected a new layer of liquidity into Adicet Bio’s equity. The largest single transaction – a 40,416‑share sale by OrbiMed Israel Partners II, L.P. – was executed at a price of $6.52, just shy of the current market price of $6.86. In the same window, OrbiMed Genesis Master Fund unloaded 78,499 shares at $6.29. These sales collectively reduced the holdings of the principal OrbiMed entities to zero in the short‑term, although the broader OrbiMed umbrella remains heavily invested across several vehicles, holding more than 600,000 shares in total.

What Does the Timing Tell Investors?

The timing of these sell‑orders is telling. They coincide with a broader trend of insider activity at Adicet, where key executives—Chief Financial Officer Harvey Nicholas, President & CEO Schor Chen, and others—have been exercising stock options and making modest secondary sales. While option exercises reflect confidence in the company’s pipeline, the concurrent off‑market sales by OrbiMed suggest a strategic realignment of portfolio exposure. For investors, this could signal a cautious approach to the near‑term valuation, especially given the company’s recent 24.25% yearly decline and a negative price‑earnings ratio. The sell‑pressure may also reflect a hedge against potential volatility in the coming quarter as Adicet progresses through clinical milestones.

OrbiMed’s Historical Pattern: From Aggressive Accumulation to Gradual Divestment

OrbiMed Advisors LLC’s transaction history at Adicet is characterized by a dramatic shift. In October 2025, the firm executed two sizeable purchases—1.5 million and 3.5 million shares—at $1.00 each, cementing a dominant stake of roughly 13 million shares. Over the next six months, OrbiMed maintained sizeable holdings (over 1 million shares across several vehicles) while only making incremental sales. The April 2026 sell‑cluster marks a pivot: the firm is now systematically liquidating portions of its holdings, likely in compliance with Rule 144 to release shares for public trading. This pattern reflects a broader industry trend where private‑equity‑backed biotech investors accumulate during early development and gradually divest as the company matures, balancing liquidity needs with long‑term value creation.

Implications for Adicet’s Strategic Outlook

With a market cap of $69 million and a 52‑week low of $6.01, Adicet remains a high‑risk, high‑reward play. The influx of liquid shares may temporarily tighten the supply, potentially exerting downward pressure on the stock price. However, the continued presence of substantial OrbiMed holdings across multiple funds suggests ongoing institutional support. For investors, the key signals are twofold: first, monitor the company’s upcoming clinical data releases, which could either justify a price rebound or trigger further sell‑pressure; second, keep an eye on future Rule 144 filings from OrbiMed, as any significant re‑allocation could further influence share liquidity and pricing dynamics.

Conclusion

The recent OrbiMed sell‑orders inject a fresh wave of activity into Adicet’s insider landscape, reflecting a strategic recalibration by a major institutional stakeholder. While the transactions add short‑term liquidity, they also underscore the delicate balance between institutional support and investor sentiment. For the broader market, these moves serve as a reminder that even well‑positioned biotech firms can experience volatile share dynamics when institutional owners shift their portfolios in response to evolving clinical and financial realities.